• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

byDeepti Shroff Karhade
July 16, 2022
in COVID-19 Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Patients hospitalized with COVID-19 and treated with dexamethasone experienced lower 28-day mortality compared to those treated with usual care.

2. Patients treated with dexamethasone had a shorter hospitalizations compared to those in the usual care group.

Original Date of Publication: February 2021

Study Rundown: Although the majority of coronavirus disease 2019 (COVID-19) cases are asymptomatic or have minor symptoms, many patients need hospital care and can progress to respiratory failure and require ventilatory support. Furthermore, no therapeutic agent had been shown to reduce mortality in patients with more severe COVID-19 infections. This study assessed the use of dexamethasone in patients hospitalized with COVID-19. The study found that patients treated with dexamethasone experienced significantly lower mortality at 28 days when compared to patients in the usual care group. No benefit was found amongst patients who did not require supplemental oxygen therapy. Patients treated with dexamethasone were also noted to have shorter hospitalizations and a greater probability of being discharged within 28 days. The study was limited by the lack of long-term follow-up in patients treated with dexamethasone. Nonetheless, this was the first study to find a therapy that effectively prevented disease progression and lowere mortality in patients with severe COVID-19 infection.

Click to read the study in NEJM

In-Depth [randomized control trial]: This controlled, open-label trial enrolled 6425 patients. Eligible patients included those with confirmed SARS-CoV-2 infection, hospitalized for severe symptoms, and on ventilation or oxygen support. Patients were excluded if dexamethasone was not available at the hospital. Randomization occurred in a 2:1 ratio to receive either usual care alone or usual care plus dexamethasone (oral or IV 6 mg daily), respectively. The primary endpoint was all-cause mortality within 28 days after randomization. Overall, mortality at 28 days was significantly lower in the dexamethasone group (22.9%) compared to patients in the control group (25.7%) (rate ratio 0.83; 95%CI 0.75-0.93; p < 0.001). Subgroup analysis showed there was no benefit in treating patients who did not receive respiratory support in the form of supplemental oxygen with dexamethasone (17.8%) compared to usual care alone (14.0%) (rate ratio 1.19; 95%CI 0.92-1.55). Furthermore, patients treated with dexamethasone had a shorter duration in hospital stay compared to the control group (median 12 vs 13 days). Finally, patients treated with dexamethasone had a greater probability of discharge after 28 days when compared to usual care alone (rate ratio 1.10; 95%CI 1.03-1.17). Overall, dexamethasone was shown to decrease all-cause mortality, shorten the duration of hospitalization, and improve the probability of discharge in hospitalized patients with COVID-19.

RELATED REPORTS

High-flow nasal cannula oxygen compared with standard oxygen therapy not associated with significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-COVID Randomized Clinical Trial

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021 Feb 25;384(8):693–704.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #COVID mortality#severe COVID-19dexamethasonehospitalization
Previous Post

Nationwide vaccination campaign with BNT162b2 mRNA vaccine reports high immunogenicity across all age groups [Classics Series]

Next Post

#VisualAbstract: Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients with Persistent Atrial Fibrillation

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High-flow nasal cannula oxygen compared with standard oxygen therapy not associated with significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-COVID Randomized Clinical Trial

October 2, 2022
VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Emergency

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

November 21, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

September 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization [Classics Series]

July 18, 2022
Next Post
#VisualAbstract: Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients with Persistent Atrial Fibrillation

#VisualAbstract: Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients with Persistent Atrial Fibrillation

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Interleukin-6 receptor antagonist treatment improves outcomes in patients with COVID-19 infection [Classics Series]

Exercise delivered via telehealth is effective for chronic disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options